Loading...
A paradigm shift in biomarker guided oncology drug development
Over the past couple of decades, biomarker driven enrichment clinical trials have proven to be an important tool in clinical drug development, especially for targeted anti-cancer drugs. By the end of 2018, more than 30 drugs have been developed in conjunction with a biomarker test and have a regulat...
Na minha lista:
| Udgivet i: | Ann Transl Med |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AME Publishing Company
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6511563/ https://ncbi.nlm.nih.gov/pubmed/31157269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.03.36 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|